Stock MRNA MODERNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/05/2024 BST 		5-day change 1st Jan Change
111.5 USD +1.04% Intraday chart for Moderna, Inc. +3.31% +12.08%
04-30 Moderna's Top-Line Sales Seen to Start Growing in 2025, Oppenheimer Says MT
04-30 Wall Street: buoyed by Tesla, confident ahead of FOMC meeting CF

Business Summary

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:

- revenue from product sales (95.7%) ;

- revenues from grants (4%);

- revenues from collaboration agreements (0.3%).

At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.

Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Number of employees: 5,600

Sales per Business

USD in Million2022Weight2023Weight Delta
Messenger RNA (mRNA) Medicines
100.0 %
19,263 100.0 % 6,848 100.0 % -64.45%

Sales per region

USD in Million2022Weight2023Weight Delta
Rest of World
52.5 %
7,298 37.9 % 3,598 52.5 % -50.70%
United States
27.7 %
5,150 26.7 % 1,895 27.7 % -63.20%
Europe
19.8 %
6,815 35.4 % 1,355 19.8 % -80.12%

Managers

Managers TitleAgeSince
Stéphane Bancel CEO
 Chief Executive Officer 51 28/02/11
James Mock DFI
 Director of Finance/CFO 47 05/09/22
Stephen Hoge PSD
 President 48 31/12/12
Brad Miller CTO
 Chief Tech/Sci/R&D Officer - 02/01/23
Jerh Collins CTO
 Chief Tech/Sci/R&D Officer - 31/12/22
Lavina A. Talukdar IRC
 Investor Relations Contact - 31/03/19
Jonathan Hoggatt PRN
 Corporate Officer/Principal - -
José M. Vega PRN
 Corporate Officer/Principal - 10/01/21
Jacqueline Miller PRN
 Corporate Officer/Principal - 10/05/20
Charbel Haber LAW
 General Counsel - 20/04/20

Members of the board

Members of the board TitleAgeSince
Paul Sagan BRD
 Director/Board Member 65 31/05/18
Elizabeth Tallett BRD
 Director/Board Member 74 30/06/20
Francois Nader BRD
 Director/Board Member 67 10/12/19
Noubar Afeyan FOU
 Founder 60 31/12/09
Robert Langer FOU
 Founder 75 31/12/09
Stéphane Bancel CEO
 Chief Executive Officer 51 28/02/11
Sandra Horning BRD
 Director/Board Member 75 29/02/20
Elizabeth Nabel BRD
 Director/Board Member 72 30/11/15
Stephen Berenson BRD
 Director/Board Member 63 30/09/17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 382,879,612 346,081,519 ( 90.39 %) 0 90.39 %

Shareholders

NameEquities%Valuation
Baillie Gifford & Co.
11.92 %
45,654,527 11.92 % 4 865 M $
The Vanguard Group, Inc.
10.20 %
39,036,765 10.20 % 4 160 M $
Vanguard Fiduciary Trust Co.
8.856 %
33,907,072 8.856 % 3 613 M $
Stéphane Bancel
5.504 %
21,075,476 5.504 % 2 246 M $
BlackRock Advisors LLC
5.205 %
19,929,660 5.205 % 2 124 M $
STATE STREET CORPORATION
3.819 %
14,623,723 3.819 % 1 558 M $
Robert Langer
3.006 %
11,509,357 3.006 % 1 226 M $
Flagship Pioneering
2.525 %
9,666,038 2.525 % 1 030 M $
Thélème Partners LLP
1.920 %
7,349,456 1.920 % 783 M $
Wellington Management Co. LLP
1.887 %
7,225,579 1.887 % 770 M $

Holdings

NameEquities%Valuation
GENERATION BIO CO.
8.81%
 5,859,375 8.81% 23,847,656 $
METAGENOMI, INC.
4.55%
 1,707,473 4.55% 18,013,840 $
CARISMA THERAPEUTICS, INC.
12.54%
 5,059,338 12.54% 11,484,697 $

Company contact information

Moderna, Inc.

200 Technology Square

02139, Cambridge

+617 714 6500

http://www.modernatx.com
address Moderna, Inc.(MRNA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
110.3 USD
Average target price
134.3 USD
Spread / Average Target
+21.75%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+12.08% 42.24B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.19B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 10.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 9.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. Company Moderna, Inc.